Edition:
United States

FibroGen Inc (FGEN.O)

FGEN.O on Nasdaq

47.21USD
18 Apr 2019
Change (% chg)

$1.07 (+2.32%)
Prev Close
$46.14
Open
$46.33
Day's High
$47.64
Day's Low
$45.00
Volume
1,092,031
Avg. Vol
704,440
52-wk High
$68.55
52-wk Low
$37.27

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $4,039.40
Shares Outstanding(Mil.): 85.56
Dividend: --
Yield (%): --

Financials

  FGEN.O Industry Sector
P/E (TTM): -- 103.27 57.80
EPS (TTM): -1.04 -- --
ROI: -11.04 7.81 11.82
ROE: -16.66 7.87 12.64

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Dec 18 2018

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON, Dec 18 China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Dec 18 2018

Earnings vs. Estimates